Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) EBITDA (2016 - 2025)

Historic EBITDA for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to -$485000.0.

  • Guided Therapeutics' EBITDA rose 1354.72% to -$485000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.2 million, marking a year-over-year decrease of 660.19%. This contributed to the annual value of -$2.1 million for FY2024, which is 3902.23% up from last year.
  • According to the latest figures from Q3 2025, Guided Therapeutics' EBITDA is -$485000.0, which was up 1354.72% from -$763000.0 recorded in Q2 2025.
  • Guided Therapeutics' EBITDA's 5-year high stood at -$359000.0 during Q1 2024, with a 5-year trough of -$1.5 million in Q2 2023.
  • Over the past 5 years, Guided Therapeutics' median EBITDA value was -$561000.0 (recorded in 2021), while the average stood at -$677105.3.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 24008.26% in 2021, then surged by 5741.4% in 2024.
  • Guided Therapeutics' EBITDA (Quarter) stood at -$435000.0 in 2021, then crashed by 117.93% to -$948000.0 in 2022, then soared by 48.84% to -$485000.0 in 2023, then decreased by 10.1% to -$534000.0 in 2024, then increased by 9.18% to -$485000.0 in 2025.
  • Its EBITDA stands at -$485000.0 for Q3 2025, versus -$763000.0 for Q2 2025 and -$414000.0 for Q1 2025.